RxDoctor Payments Data

Steven Trocha, MD

Surgical Oncology · Greenville, SCNPI 1346280757

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $46,665 of the $56,848 with a category attached, or 82.1%. Medical Device Business Services, Inc. accounts for 72.4% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2021 at $29,761 and has fallen 98.5% since, to $439 in 2025.

$56,848in general payments, 2019–2025

Across 95 payments — averaging $598.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$41K
  • Boston Scientific$7K
  • Johnson & Johnson$5K
  • Incyte Corporation$925
  • Stryker$763
  • Ethicon Endo-surgery Inc.$460
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$46,66582%
  • Speaking & faculty fees$5,61310%
  • Travel & lodging$1,2512%
  • Food & beverage$3,3196%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few surgical oncology providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$169,388
Medicare patients
378
Services billed
961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone Hcl39$300
Ondansetron OdtOndansetron12$237
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$106
Tramadol Hcl16$47

Paid to pharmacies, not to this prescriber.

Other surgical oncology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →